 Royalty Pharma plc NASDAQ: RPRX and OMERS Capital Markets have announced transactions worth 350 million in new funding in BioCryst Pharmaceuticals Inc NASDAQ: BCRX. The largest buyer of pharmaceutical royalties globally, Royalty Pharma has purchased royalties for 150 million upfront on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor. 